Quick Answer
Tonix Pharmaceuticals Holding Corp. reported Research And Development Expense of $44.49 million for the year ending 2025.
- Tonix Pharmaceuticals Holding Corp. showed an increase of +11.3% in Research And Development Expense from 2024 to 2025.
- This data is from Tonix Pharmaceuticals Holding Corp.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2011: $492.0 thousand | Q1 2012: $397.6 thousand | Q2 2012: $658.1 thousand | Q3 2012: $658.1 thousand | Q1 2013: $741.0 thousand | Q2 2013: $944.0 thousand | Q3 2013: $1.64 million | Q1 2014: $3.55 million | Q2 2014: $4.08 million | Q3 2014: $5.22 million | Q1 2015: $6.83 million | Q2 2015: $8.87 million | Q3 2015: $10.31 million | Q1 2016: $10.67 million | Q2 2016: $7.52 million | Q3 2016: $5.47 million | Q1 2017: $2.99 million | Q2 2017: $2.81 million | Q3 2017: $3.91 million | Q1 2018: $5.17 million | Q2 2018: $4.07 million | Q3 2018: $3.26 million | Q1 2019: $3.90 million | Q2 2019: $3.55 million | Q3 2019: $5.05 million | Q1 2020: $4.68 million | Q2 2020: $10.57 million | Q3 2020: $8.81 million | Q1 2021: $15.33 million | Q2 2021: $18.13 million | Q3 2021: $13.08 million | Q1 2022: $18.42 million | Q2 2022: $16.58 million | Q3 2022: $22.20 million | Q1 2023: $26.51 million | Q2 2023: $21.98 million | Q3 2023: $21.05 million | Q1 2024: $12.86 million | Q2 2024: $9.70 million | Q3 2024: $9.11 million | Q1 2025: $7.44 million | Q2 2025: $10.82 million | Q3 2025: $9.29 million.
- Over the full 16 years of available data (2010 to 2025), Tonix Pharmaceuticals Holding Corp.'s Research And Development Expense has grown by 7,513.6%.
- Historical annual values: Fiscal year 2025: $44.49 million | Fiscal year 2024: $39.97 million | Fiscal year 2023: $86.66 million | Fiscal year 2022: $81.88 million | Fiscal year 2021: $68.84 million | Fiscal year 2020: $36.16 million | Fiscal year 2019: $18.19 million | Fiscal year 2018: $17.56 million | Fiscal year 2017: $13.34 million | Fiscal year 2016: $28.53 million | Fiscal year 2015: $35.50 million | Fiscal year 2014: $18.62 million | Fiscal year 2013: $4.65 million | Fiscal year 2012: $2.58 million | Fiscal year 2011: $1.16 million | Fiscal year 2010: $584.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: